Articles tagged with Kidney Cancer
A new study suggests that recurring infections could lead to delayed diagnoses of bladder or kidney cancer in women. Analysis of over 100,000 people found that many with blood in their urine had no check-up after initial UTI symptoms.
A new therapeutic target has been identified for aggressive pediatric cancers with few treatment options. The researchers discovered that malignant rhabdoid tumors may be sensitive to drugs that block the cancer cell's ability to dispose of misfolded proteins, and a Phase II clinical trial is underway to investigate this approach.
A study of 2,766 physicians found that those receiving payments from a cancer drug's manufacturer were more likely to prescribe the drug for certain types of cancer, including kidney and lung cancer. Financial relationships between physicians and drug companies can influence prescribing practices.
Scientists at Sechenov University have discovered a new highly sensitive and quick method for diagnosing kidney cancer using antibodies to a retina protein. The method measures the immune response to arrestin-1, which is synthesized in cancerous cells of kidneys, and has been shown to detect benign growths at early stages.
A new study has identified specific obesity-related factors that increase the risk of developing renal cell carcinoma, a type of kidney cancer. These factors include multiple measures of obesity, diastolic blood pressure, and fasting insulin, but not systolic blood pressure or circulating lipids.
Two new studies published in the British Journal of Cancer reveal alarming breast cancer risks for women with false-positive screening results. Women who experience a first false-positive result have a two-fold risk of developing screen-detected or interval breast cancer later in life, while those with a second false-positive result fa...
The burden of chronic kidney disease is increasing substantially over the past 15 years in all 50 US states, with rates accelerating faster than other noninfectious diseases. The condition is particularly concerning for younger adults, who are experiencing a significant increase in deaths due to kidney disease.
A new study published in eLife suggests that activating the protein ISGF3 could be a novel therapeutic strategy for patients with clear cell renal cancer. ISGF3 regulates key tumor suppressor genes and acts as a brake on tumor growth, which can be disabled by loss of secondary tumor suppressors.
A team of researchers, led by Dr. El Bachir Affar and Dr. Marc Therrien, has made a groundbreaking discovery about the molecular mechanisms that prevent cancer from developing. They found that protein BAP1 works in tandem with partner ASXL2 to protect cells and keep organs cancer-free.
A new study shows that stereotactic ablative radiotherapy (SABR) is as safe and effective for patients with one kidney as it is for those with two. The treatment provided high local control and cancer-specific survival rates, with minimal impact on renal function.
The combination of avelumab and axitinib improved progression-free survival (PFS) by 6.6 months in previously untreated patients with advanced renal cell carcinoma, with confirmed objective response rates of 55.2% and 25.5%. The study's findings support the potential of this new treatment approach for patients with advanced RCC.
A stage four sarcomatoid kidney cancer patient has achieved complete response to immunotherapy treatment, marking a significant breakthrough in the fight against this aggressive form of cancer. Researchers are now recruiting patients with sarcomatoid kidney cancer in clinical trials with checkpoint inhibitors.
Scientists have solved the structure of two proteins that control DNA packaging, potentially providing insights into why some people are at risk of developing specific cancers. The findings also shed light on how these proteins' mutations contribute to various types of cancer, including mesothelioma and leukemia.
Researchers at Wayne State University have developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs to reverse drug-resistance in renal cell carcinoma. The technology uses tumor hypoxia-directed nanoparticles to target the root cause of the problem and has shown promising results in animal trials.
Researchers developed a novel approach using glucose to assess how kidney cancer tumors use glucose. The study found that ccRCC tumors process glucose differently than most tissues, providing a potential target for new treatments.
A blood test using a protein called KIM-1 can detect kidney cancer up to five years prior to clinical diagnosis. Elevated KIM-1 concentrations in the blood are associated with poorer survival rates in patients diagnosed with renal cell carcinoma.
Researchers have identified a blood biomarker called KIM-1 that can predict the risk of developing kidney cancer over the next 5 years. Measuring levels of KIM-1 in the blood may help detect kidney cancer earlier, potentially improving survival rates.
A blood test using Kidney-injury-molecule-1 (KIM-1) can predict clear cell kidney cancer risk and survival up to five years before diagnosis, with higher levels associated with poorer outcomes. The test substantially improves accuracy in predicting kidney cancer risk.
Researchers identified specific gene activity in each cell, revealing that Wilms' tumour cells have the same characteristics as normal developing kidney cells. Adult renal carcinoma cells were found to be a version of rare healthy adult kidney cells called PT1.
Researchers at UT Southwestern Medical Center have uncovered the means by which pediatric kidney cancer continues to grow, providing potential targets for more effective treatments. Impairment of miRNA function drives Wilms tumor formation through increased IGF2 production.
Researchers discovered a new protein, ZHX2, that over-accumulates in cells lacking VHL gene function, promoting cancerous growth and potentially serving as a novel therapeutic target for clear cell renal cell carcinoma. The study's findings suggest a potential new approach to treating the most common type of kidney cancer.
A study by Keck School of Medicine found that robotic partial nephrectomy significantly reduces complications, mortality, and readmission compared to open or laparoscopic techniques. The technique offers superior patient outcomes while preserving kidney function.
UT Southwestern investigators discovered a missing link in kidney cancer prognosis by analyzing neighboring cells. They found that tumors with an inflamed neighborhood were more likely to be associated with aggressive cancers and worse survival rates. However, these tumors may respond better to immunotherapy treatment.
Avoiding excess body weight and maintaining a stable weight in middle adulthood may help prevent several obesity-related cancers in women. High weight gain is associated with a significantly increased risk of pancreatic cancer, breast cancer, and endometrial cancer.
Researchers at the University of Pennsylvania School of Medicine identified depleted metabolic enzymes as a key factor promoting tumor growth in kidney cancer. The study found that these enzymes are universally depleted in ccRCC tumors, which could lead to new treatment options for patients.
A study published in Kidney Cancer found that non-aspirin NSAID use was associated with shorter overall survival time for patients with metastatic renal cell carcinoma. The use of these medications can cause kidney-specific toxicity, leading to increased blood pressure and decreased renal function.
Researchers have identified key molecular events and genomic profiles in clear-cell renal carcinoma, a type of kidney cancer. The study's findings could lead to the prediction of metastasis patterns and potentially inform new treatment strategies.
The US FDA approved the combination of ipilimumab and nivolumab for metastatic kidney cancer patients. The treatment led to a 37% improvement in survival compared to sunitinib and durable responses in 42% of patients.
Scientists identified critical genetic changes that can lead to kidney cancer, with the first mutation occurring in childhood or adolescence. The findings suggest that early detection and intervention may be possible, particularly for high-risk groups.
Researchers discovered three evolutionarily distinct types of kidney cancer, each with its own evolutionary path. The study sheds light on the fundamental principles of cancer evolution and could lead to future clinical tests for more accurate prognoses and personalized treatment.
A new study by researchers at Washington University School of Medicine found that women with kidney cancer who have substantial abdominal fat are more likely to die within 3 1/2 years after diagnosis, while those with little belly fat tend to live longer. For men, the amount of abdominal fat does not appear to affect survival rates.
Patients with urological cancers, such as prostate and bladder cancer, are five times more likely to commit suicide than the general population. The study found that severe psychological stress is a major side-effect of cancer diagnosis and treatment, leading to higher rates of depression, PTSD, and suicidal intent in this patient group.
A study combining axitinib and pembrolizumab found the treatment to be tolerable and doubling efficacy in patients with advanced kidney cancer. Over 90% of patients exhibited tumor shrinkage, keeping disease under control for over 20 months.
Researchers at Dana-Farber Cancer Institute have identified a genetic mechanism that influences whether cancer cells resist or respond to immunotherapy drugs. The discovery reveals potential new drug targets and may aid efforts to extend the benefits of immunotherapy treatment to more patients.
Researchers at UT Southwestern Medical Center have developed a new Magnetic Resonance Imaging (MRI) technology that can accurately diagnose the nature and aggressiveness of kidney cancer without the need for invasive biopsies. This breakthrough technology, known as multiparametric MRI, uses multiple types of images to evaluate the chem...
A new class of medicines called HIF-2a inhibitors, including PT2385, have shown promise in treating metastatic kidney cancer. The drug blocked tumor growth for at least 4 months in 40% of patients and stopped cancer growth for over a year in 25% of patients with minimal side effects.
A new study found that only a quarter of UK adults understand the connection between weight issues and cancer, despite obesity being linked to 13 types of cancer. The study also highlighted misconceptions about cancer types linked to obesity and the impact of socio-economic background on awareness.
Researchers tracked mortality rates in Chileans exposed to arsenic-contaminated drinking water, finding increased risk of lung, bladder, and kidney cancer up to 40 years after exposure ended. Long-term interventions may help mitigate the effects of past exposures.
A new study published in Nature Communications describes the unique role of androgens in kidney cancer, suggesting a potential new approach to treatment. Researchers found that androgen signaling can either stimulate or suppress tumor cell movement and invasion, with male patients being more likely to spread to the lungs.
M. Celeste Simon, a renowned Penn Cancer biologist, has been awarded the National Cancer Institute Outstanding Investigator Award. She is recognized for her groundbreaking research on cancer cell metabolism and its applications in treating clear cell renal cell carcinoma.
A study published in Kidney Cancer journal found a decline in California kidney cancer incidence rates from 2009 to 2013, with stabilization of the trend. The research also showed an increase in partial nephrectomies, a surgical treatment that preserves long-term kidney function.
A new study found that the combination of nivolumab and ipilimumab therapy demonstrates manageable safety, notable antitumor activity, and durable responses with promising long-term overall survival in patients with metastatic renal cell cancer. The treatment shows enhanced antitumor activity compared to monotherapy in tumor types such...
A new combination immunotherapy has significantly improved response rates for kidney cancer patients, with 40% experiencing prolonged responses. This treatment approach has the potential to set a new standard of care for kidney cancer patients, offering durable and reversible side effects compared to current therapies.
Researchers found that savolitinib, a MET inhibitor, showed significant tumor shrinkage and stable disease in 18% of patients with MET-driven papillary renal cell carcinoma. The treatment was generally well-tolerated, with longer time to cancer progression in MET-driven tumors compared to those without the abnormality.
A new mouse model has been created to investigate kidney cancer, allowing researchers to develop better treatments. The model reveals that gene mutations in the primary cilium contribute to renal cell carcinoma's progression.
A new combination immunotherapy has shown promise in treating advanced kidney cancer, with the potential to identify biomarkers for many cancers. The study's principal investigator, Dr. Timothy Kuzel, hopes that this treatment will help more patients benefit from immunotherapy.
Researchers have created detailed atlases of immune cells surrounding human tumors, revealing unique profiles that can estimate cancer prognosis and identify potential targets for early immunotherapy. The findings have the potential to inspire new precision immunotherapy clinical trials.
A comprehensive atlas of immune cells in renal cancer has been created, revealing new relationships between immune cells and their role in disease progression. The study identified specific protein structures on the surface of immune cells that can help tailor treatments to individual patients.
Researchers have developed a novel fruit fly model of kidney cysts, enabling the deciphering of biochemical pathways in polycystic kidney disease and cancer. The findings will help identify new treatment targets and methods for certain kidney diseases and cancers.
A recent study published in The Journal of Urology found that surgery to remove secondary tumor growths, called metastases, significantly improves survival rates for patients with late-stage kidney cancer. Patients who underwent surgery had a life expectancy of three to 12 years, compared to eight months and two years without surgery.
A study of 151 patients with metastatic kidney cancer found that 85 had lung cancer metastasis, but only three had a primary lung cancer tumor that went undiagnosed. This discovery highlights the importance of medical oncologists and radiologists being aware of hidden lung cancers in kidney cancer patients.
Researchers tested over 400 fast food packaging samples and found 56% of dessert and bread wrappers contain PFASs, linked to kidney and testicular cancers, thyroid disease, and immunotoxicity. The study calls for nontoxic alternatives in packaging to reduce health risks.
A study found that inhibiting CCR4 in a mouse model of renal cell carcinoma reduced tumor proliferation and changed the composition of immune cells. The results suggest anti-CCR4 antibodies as a potential therapeutic for multiple cancers linked to abnormal CCR4 expression.
A combination of steroids and sirolimus with immune checkpoint inhibitors may help prevent organ rejection in kidney transplant patients undergoing cancer treatment. This discovery shows promise for people with cancer who have also had a kidney transplant, potentially allowing them to receive full benefits from immunotherapy.
In a phase I clinical trial, combination therapy of CB-839 and everolimus resulted in tumor control in 93% of patients with clear cell and papillary renal cell cancer. The median time without cancer growth was 8.5 months, suggesting potential as a treatment option for advanced kidney cancer.
Researchers at Dana-Farber Cancer Institute found that cabozantinib exceeded sunitinib in progression-free survival and overall response rates for patients with metastatic kidney cancer. The study showed a 20% lower risk of death associated with cabozantinib treatment.
A successful trial shows that taking oral tablet Sunitinib for one year reduces the likelihood of kidney cancer returning for patients following removal of the kidney. The treatment improves disease-free survival and reduces the risk of relapse by 40-50% compared to placebo.
Cabozantinib significantly improves progression-free survival and response rate in patients with intermediate or poor-risk clear-cell metastatic renal cell carcinoma compared to sunitinib. The study also found a higher objective response rate in the cabozantinib arm.
A phase III trial has met its primary endpoint, demonstrating improved disease-free survival with sunitinib in high-risk renal cell carcinoma patients after nephrectomy. The treatment showed a significantly longer disease-free survival of 6.8 years compared to 5.6 years with placebo.
Researchers are investigating the role of SLC13A3, a likely tumor suppressor gene, in kidney cancer. They hope to understand why its expression is suppressed in African American patients and explore its potential as a therapeutic target.